Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets.
The Food and Drug Administration on Thursday notified health professionals, their provider organizations and caregivers for infants, that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain.
Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.
The Advisory Committee on Immunization Practices on Wednesday voted to recommend a preference for using the nasal spray flu vaccine instead of the flu shot in healthy children ages 2 years to 8 years of age when it is immediately available.
The Congressional Wellness Caucus and the Partnership to Fight Chronic Disease on Thursday hosted a briefing to examine the impact of chronic, non-communicable disease and look beyond just medical costs to more holistically consider total productivity, particularly among the federal workforce.
Slightly more than half of all seniors who are not in an assisted living situation reported having issues with incontinence, according to a report released Wednesday by the Centers for Disease Control and Prevention.
Patients with chronic obstructive pulmonary disease may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition, according to key findings from a two-part national COPE (Chronic Obstructive Pulmonary Experience) Survey initiative released last week by the COPD Foundation.
After a five-year contraction in employer healthcare spending growth, medical inflation in the United States is projected to rise to 6.8% in 2015, according to PricewaterhouseCoopers’ Health Research Institute.
Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.
Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.
A survey co-released on Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that the healthcare providers patients rely on most to explain safety information about their prescription drugs have serious concerns about a proposed FDA rule on generic drug labeling.
A survey co-released Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.